Komori
Results4881FunPep Company LimitedPharmaceuticals

FY2026 December 3Q Financial Results Summary [Japanese GAAP] (Consolidated)

Cumulative business revenue for the first 3 quarters increased to ¥2 million, while operating loss changed from ¥1,253 million in the same period of the previous year to ¥786 million. Although the deficit narrowed as development costs for FPP004X and other expenses declined, operating, ordinary and net income all remained in the red.

Worth reading
44Recurring
Scored from 5 of 6 sections
Direction
Improvement
Direction inferred from the company’s description.
Scale
467
¥ million
Wording
Conditional
How definitive the wording is.

Results for this period

Third quarter1 January 2026 to 30 September 2026ConsolidatedJapanese GAAP
Net Sales2¥ millionYear on year +572.8%
Operating profit-786¥ million
Ordinary income-781¥ million
Net income attributable to owners of the parent-813¥ million

The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit.

Net income per share-¥17.38
Financial position at period-end
Total assets1,865¥ million
of which net assets 1,428 ¥ millionEquity ratio 75.1%vs. prior year-end +2.4pt

塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.

Outlook and shareholder returns
Annual Dividend Forecast¥0.00 → ¥0.00（0.0）
Factors Behind Changes in Business Performance

Research and development expenses decreased by ¥440 million year on year due to lower development costs for FPP004X, while other selling, general and administrative expenses also decreased by ¥25 million. Business revenue included ¥2 million in sales of functional peptides for the cosmetics sector and other applications.

Disclosure regarding the going concern assumption

Not applicable

Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 No
Changes in the scope of consolidationNew 0 companies / Excluded 0 companies / Company name No
Breakdown of extraordinary income (loss)Extraordinary income Item Gain on reversal of subscription rights to shares / Amount ¥480 thousand / Extraordinary loss Item Impairment loss on investment securities / Amount ¥29,970 thousand
Depreciation and amortization¥722 thousand
Availability of Supplementary Financial Results MaterialsNo
Availability of Financial Results BriefingNo
Issued Shares at Period-End50,666,700 shares
Treasury Shares at Period-End12 shares
Results for this period
ItemDetails
Fiscal Period ClassificationThird quarter
Accounting standardsJapanese GAAP
Consolidated / non-consolidatedConsolidated
Period Covered1 January 2026 to 30 September 2026
Net Sales¥2 million (YoY +572.8%)
Operating profit¥-786 million
Ordinary income¥-781 million
Profit attributable to owners of the parent¥-813 million
Net income per share-¥17.38
Equity ratioEnd of the current fiscal period 75.1 / End of previous period 72.7
Total assets¥1,865 million
Net assets¥1,428 million
Annual Dividend Forecast¥0.00 → ¥0.00（0.0）
Depreciation and amortization¥722 thousand
Breakdown of extraordinary income (loss)Extraordinary income Item Gain on reversal of subscription rights to shares / Amount ¥480 thousand / Extraordinary loss Item Impairment loss on investment securities / Amount ¥29,970 thousand
Disclosure regarding the going concern assumptionNot applicable
Change in accounting policyChanges due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No
Changes in the scope of consolidationNew 0 companies / Excluded 0 companies / Company name No
Availability of Supplementary Financial Results MaterialsNo
Availability of Financial Results BriefingNo
Issued Shares at Period-End50,666,700 shares
Treasury Shares at Period-End12 shares
Factors Behind Changes in Business PerformanceResearch and development expenses decreased by ¥440 million year on year due to lower development costs for FPP004X, while other selling, general and administrative expenses also decreased by ¥25 million. Business revenue included ¥2 million in sales of functional peptides for the cosmetics sector and other applications.
Items this document does not state (15)
Operating MarginCash flows from operating activitiesCash flows from investing activitiesCash flows from financing activitiesCash and cash equivalents at end of periodFull-year earnings forecastRevision to Earnings ForecastPayout ratioShareholder Return PolicySegment revenueSegment profitRegional salesOrders received and order backlogImpairment lossMaterial subsequent events

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Research and development expenses decreased by ¥440 million due to lower development costs for FPP004X, while other selling, general and administrative expenses also decreased by ¥25 million.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
FY2026 December 3Q Financial Results Summary [Japanese GAAP] (Consolidated) | FunPep Company Limited (4881) timely disclosure | Komori